Clinical Efficacy of Dengyin Naotong Capsule for Cognitive Impairment Related to Cerebral Small Vascular Disease

Qian Ma¹, Bao Nan², Xi Yu³, Qing-tao Ren^1, and Qing-hua Zhang^4,

¹Department of Psychiatry, Zibo City Fifth People’s Hospital, Zibo 255100, China

²Department of Medical Records, The First Hospital of Zibo, Zibo 255200, China

³Institute of Integrative Medicine,Qingdao University Medical College, Qingdao 266021,China

⁴Shandong Public Health Clinical Center, Shandong University, Jinan 250013, China

Cite this paper:
Qian Ma, Bao Nan, Xi Yu, Qing-tao Ren and Qing-hua Zhang. Clinical Efficacy of Dengyin Naotong Capsule for Cognitive Impairment Related to Cerebral Small Vascular Disease. American Journal of Pharmacological Sciences. 2024; 12(3):40-45. doi: 10.12691/ajps-12-3-3

Abstract

Objective: This study aims to investigate the clinical efficacy of Dengyin Naotong (DYNT) capsule for cognitive impairment related to cerebral small vascular disease (CSVS). Methods: Total of 105 patients with cognitive impairment related to CSVD hospitalized in Zibo Fifth People's Hospital from July 2021 to June 2023 were selected and randomly divided into control group (53 cases) and treatment group (52 cases). The patients in control group were treated with anti-arteriosclerosis, anti-platelet aggregation, nicergoline treatment, etc. while in treatment group combined with DYNT capsule on the basis of control group for 6 months both in the two groups. Before and after treatment, the Mini-mental State Examination (MMSE), Montreal Cognitive Assessment Scale (MoCA), Ability of Daily Living (ADL) score, Tinetti Balance and Gait Assessment Scale (POMA) score, Traditional Chinese Medicine Syndrome Scores (TCMSS), and the plasma levels of homocysteine (Hcy), C reactive protein (CRP) and D-dimer of patients were observed. Results: After treatment, the MMSE scores, MoCA scores ADL scores and POMA scores of patients increased significantly than those before treatment (P<0.05) both in the two groups, and which in the treatment group were significantly higher than those in the control group (P<0.05). After treatment, the TCMSS of patients decreased significantly than those before treatment (P<0.05) both in the two groups, and which in the treatment group was significantly lower than that in the control group (P<0.05). After treatment, the plasma levels of Hcy, CPR and D-dimer both in the two groups were significantly lower than before treatment (P<0.05), and which in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion: DYNT capsule has some clinical efficacy in the treatment of cognitive impairment related to CSVD.

Keywords:
Dengyin Naotong capsule cerebral small vascular disease cognitive impairment MMSE MoCA ADL POMA TCMSS

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Hachinski V. World Stroke Day 2008: Little strokes, big trouble. Stroke, 2008, 39(9): 2407-2408.
[2]	Thompson CS, Hakim AM. Living beyond our physiological means:small vessel disease of the brain is an expression of a systemic failure in arteriolar function: a unifying hypothesis. Stroke, 2009, 40: e322-e330.
[3]	Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol, 2010, 9(7): 689-701.
[4]	Ihara M. Management of cerebral small vessel disease for the diagnosis and treatment of dementia. Brain Nerve, 2013, 65(7): 801-809.
[5]	Jellinger KA. Pathology and pathogenesis of vascular cognitive impairment -- a critical update. Front Aging Neurosci, 2013, 5: 1-17.
[6]	Pavlovic AM, Pekmezovic T, Tomic G, et al. Baseline predictors of cognitive decline in patients with cerebral small vessel disease. J Alzheimers Dis, 2014, 42: S37-S43.
[7]	Loitfelder M, Seiler S, Schwingenschuh P, et al. Cerebral microbleeds: a review. Panminerva Med, 2012, 54: 149-160.
[8]	Maclullich AM, Wardlaw JM, Ferguson K J, et al. Enlarged perivascular spaces are associated with cognitive function in healthy elderly me. J Neurol Neurosurg Psychiat, 2004, 75(11): 1519-1523.
[9]	Jiang L, Cai X, Yao D, et al. Association of inflammatory markers with cerebral small vessel disease in community-based population. J Neuroinflamm, 2022, 19(1): 106.
[10]	Imamine R, Kawamura T, Umemura T, et al. Does cerebral small vessel disease predict future decline of cognitive function in elderly people with type 2 diabetes. Diabetes Res Clin Pract, 2011, 94: 91-99.
[11]	Jobson DD, Hase Y, Clarkson AN, et al. The role of the medial prefrontal cortex in cognition, ageing and dementia. Brain commun, 2021, 3(3): fcab125.
[12]	Tuladhar AM, van Uden IW, Rutten-Jacobs LC, et al. Structural network efficiency predicts conversion to dementia. Neurology, 2016, 86(12): 1112-1119.
[13]	Du J, Xu Q. Neuroimaging studies on cognitive impairment due to cerebral small vessel disease. Stroke Vas Neurol, 2019, 4(2): 99-101.
[14]	del Brutto VJ, Ortiz JG, Del Brutto OH, et al. Total cerebral small vessel disease score and cognitive performance in community dwelling older adults. Results from the Atahualpa Project. Int J Geriatr Psychiat, 2018, 33(2): 325-331.
[15]	Huijts M, Duits A, van Oostenbrugge RJ, et al. Accumulation of RI markers of cerebral small vessel disease is associated with decreased cognitive function. A study in first-ever lacunar stroke and hypertensive patients. Front Aging Neurosci, 2013, 5: 7.
[16]	Wang B. Observations on the efficacy of DYNT capsule in the treatment of sequelae of cerebral infarction. Chin J Pract Nervous Dis, 2008, 11(8): 70-71.
[17]	Wang HC, Liu J. Observation on the efficacy of DYNT combined with betahistine in the treatment of posterior circulation ischemic vertigo. Drugs Clinic, 2019, 34(8): 2338-2342.
[18]	Li T, Tang ZX, Yang H, et al. Effects of DYNT capsule on the content of monoamine neurotransmitters in the brain tissue of aging mice. Capital Med, 2010, 17(18): 49-50.
[19]	Qu YJ, Su ZQ, Li ZR, et al. Effect of DYNT capsule combined with olanzapine on efficacy and cerebral microcirculation and cognitive impairment in patients with vascular dementia. Chin J Microcirc, 2019, 29(2): 19-23.
[20]	Geriatric Neurology Group, Geriatrics Branch of the Chinese Medical Association, Chinese Writing Expert Group for the Guidelines on Cognitive Dysfunction in Cerebral Small Vessel Disease. Cerebral small vessel disease-related cognitive dysfunction Chinese diagnosis and treatment guidelines (2019). Chin J Geriatr, 2019, 38(4): 345-354.
[21]	Chinese Research Hospital Society Cerebral Small Vessel Disease Specialized Committee, Chinese Expert Consensus on the Diagnosis and Treatment of Cerebral Small Vessel Disease Writing Group. Chinese expert consensus on diagnosis and treatment of cerebral small vessel disease 2021. Chin J Stroke, 2021, 16(7): 716-726.
[22]	Wang F, Yang N, He YF, et al. Cognitive dysfunction associated with cerebral small vessel disease in Chinese medicine. Modern J Integr Tradit Chin West Med, 2021, 30(14): 1507-1510.
[23]	Ding M, He SB, Xie XH, et al. Active ingredients and mechanism of Dengyin Naotong capsules in the treatment of cognitive dysfunction based on network pharmacology. Chin Pharmaceut, 2022, 32(15): 542-49.
[24]	Guo R, Zhang S, Tu Y, et al. Therapeutic effect and mechanism of Dengyin Naotong capsule combined with agatroban in the treatment of cerebral infarction. Chin Med, 2020, 15(9): 1394-1397.
[25]	Li AG, Li GH. Determination of six active components in Dengyin Naotong capsules by HPLC-MS/MS. Chin Pharm J, 2017, 52(9): 772-776.
[26]	Liu L, Wang XS. Clinical study of DYNT capsule combined with edaravone in the treatment of acute cerebral infarction. Drugs Clinic, 2021, 36(5): 906-910.
[27]	Shi H. Clinical efficacy of Dengyinnaotong capsule combined with well point bloodletting therapy in the treatment of limb numbness caused by thalamic infarction and its effect on serum homocysteine and insulin-like growth factor II levels. Pract J Cardiac Cerebral Pneumal Vascular Dis, 2022, 30(12): 80-84.
[28]	Liu Z, Zhu ZY, Niu YY, et al. Clinical study on Dengyin Naotong capsules combined with Ginkgo Leaf Extract and dipyridamole injection in treatment of acute cerebral infarction. Drugs Clinic, 2021, 36(3): 461-465.
[29]	Gao B, Liu FL. Progress in neuroimaging of cerebral small vessel disease. Int J Med Radiol, 2011, 34(6): 518-521.
[30]	Xia M, Shou YY, Wang W, et al. Effects of DYNT capsule combined with butylphthalide soft capsule on cerebral hemodynamics and inflammatory factors in patients with acute cerebral infarction. Progress in Modern Biomedicine, 2022, 22(5): 847-851.
[31]	Yan DM, Ren C, Zheng XQ, et al. Preliminary exploration of the effect and mechanism of Dengyin Naotong capsule on blood lipids. Chin J Integr Med Cardio-Cerebrovas Dis, 2020, 18(2): 240-243.
[32]	Lu S, Xiao C, Li J. Effect of Dengyin Naotong capsule and Naoxintong capsule on plasma lipoprotein-related phospholipase A2 in convalescent cerebral infarction. Liaoning J Tradit Chin Med, 2020, 47(8): 109-111.